Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 23, 2019
Subject: Conclusion of an independent investigation by the Audit Committee regarding allegations of improper sales and distribution practices, revenue recognition irregularities, and management conduct.
Key Financial Metrics and Status
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period. Instead, it addresses the reliability of historical financial data:
- Financial Statement Reliability: The Audit Committee concluded that consolidated financial statements for fiscal years 2012 through 2016, and interim periods through Q3 2017, must be restated due to accounting irregularities.
- Guidance Status: All prior financial guidance issued for 2018 has been withdrawn. Communications regarding Q4 2017 and Q1 2018 should no longer be relied upon.
- Auditor Status: Ernst & Young LLP resigned as the independent auditor. The Company is currently seeking a new independent auditor.
- Specific Misstatement: The investigation identified a specific instance where $2.5 million in revenue was improperly recognized in Q4 2015 due to a concealed "side deal."
Material Changes and Investigation Findings
The investigation, conducted by King & Spalding LLP and KPMG LLP, reviewed over 1.5 million documents and interviewed over 85 witnesses. Key findings include:
- Revenue Recognition Violations: Former senior management employed implicit arrangements with distributors that superseded explicit contract terms. Revenue was recognized improperly, often based on distributor sales to end-customers rather than direct payment obligations, violating GAAP.
- Revenue Manipulation: Management engaged in "channel stuffing," shipping unneeded products near period-ends, booking sales to distributors in acquisition processes without payment, and utilizing "side deals" where payment was contingent on resale.
- Misrepresentations: Former executives made material misstatements and omissions to the SEC, the Board, the Audit Committee, and outside auditors regarding the nature of distributor relationships and revenue practices.
- Whistleblower Retaliation: Former management initiated "Project Snow White," utilizing secret video surveillance and targeting employees who raised concerns about accounting practices.
- Anti-Kickback Statute: The investigation identified potential compliance risks in over 80 physician and customer relationships, warranting further legal review for potential loss contingencies.
Remediation Actions
- Executive Terminations: Former Chairman/CEO Parker H. "Pete" Petit, former COO William C. Taylor, former CFO Michael J. Senken, and former Controller John Cranston departed in June 2018. Their terminations were retroactively deemed "for cause," triggering compensation recoupment.
- Internal Controls: The Company is augmenting finance staff, documenting key policies, and implementing enhanced Sarbanes-Oxley controls.
- Governance: A Chief Compliance Officer and an independent compliance department reporting to the Board have been established.
Outlook, Risks, and Contingencies
- Auditor Engagement Risk: Potential new auditors have indicated they may not accept the engagement if former CEO Mr. Petit is elected to the Board or re-hired, citing high risk.
- Legal Contingencies: The Company is evaluating legal risks related to the Anti-Kickback Statute to determine if loss contingencies must be recognized or disclosed.
- Restatement Process: The Company is working to implement a comprehensive restatement of historical financials, which will impact the accuracy of all prior reported results.
Investor Verification Checklist
- Verify the timeline and scope of the upcoming financial restatement for fiscal years 2012–2017.
- Confirm the appointment of a new independent auditor and their acceptance of the engagement.
- Monitor disclosures regarding potential loss contingencies arising from the Anti-Kickback Statute investigation.
- Review the status of compensation recoupment from terminated former executives.
- Assess the effectiveness of newly implemented internal controls and the independence of the new compliance department.